Shares of BioScrip Inc (NASDAQ:BIOS) have earned an average recommendation of “Buy” from the eight research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $5.15.
BIOS has been the subject of a number of recent research reports. Lake Street Capital lifted their price target on shares of BioScrip from $4.50 to $10.00 and gave the company a “buy” rating in a research report on Friday, December 7th. Canaccord Genuity initiated coverage on shares of BioScrip in a research report on Wednesday, December 12th. They set a “buy” rating and a $5.00 price target for the company. BidaskClub raised shares of BioScrip from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 21st. Barrington Research reissued a “buy” rating and set a $4.00 price target on shares of BioScrip in a research report on Friday, October 5th. Finally, TheStreet raised shares of BioScrip from a “d+” rating to a “c-” rating in a research report on Monday, November 26th.
Shares of NASDAQ:BIOS traded up $0.01 on Tuesday, hitting $3.87. The company had a trading volume of 23,333 shares, compared to its average volume of 926,027. BioScrip has a 1 year low of $2.31 and a 1 year high of $4.14. The stock has a market cap of $510.88 million, a price-to-earnings ratio of -8.73 and a beta of 0.61.
BioScrip (NASDAQ:BIOS) last posted its earnings results on Tuesday, November 6th. The company reported ($0.09) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.02). The firm had revenue of $181.00 million for the quarter, compared to analysts’ expectations of $171.35 million. During the same period last year, the company posted ($0.12) earnings per share. The company’s revenue for the quarter was down 8.9% on a year-over-year basis. On average, equities research analysts expect that BioScrip will post -0.33 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers raised its holdings in BioScrip by 16.9% in the second quarter. Rhumbline Advisers now owns 126,878 shares of the company’s stock worth $372,000 after buying an additional 18,372 shares during the last quarter. Bank of America Corp DE raised its holdings in BioScrip by 8.5% in the second quarter. Bank of America Corp DE now owns 243,794 shares of the company’s stock worth $714,000 after buying an additional 19,096 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its holdings in BioScrip by 77.3% in the second quarter. Metropolitan Life Insurance Co. NY now owns 45,013 shares of the company’s stock worth $132,000 after buying an additional 19,625 shares during the last quarter. Vanguard Group Inc. raised its holdings in BioScrip by 0.5% in the third quarter. Vanguard Group Inc. now owns 5,987,679 shares of the company’s stock worth $18,562,000 after buying an additional 27,904 shares during the last quarter. Finally, Vanguard Group Inc raised its holdings in BioScrip by 0.5% in the third quarter. Vanguard Group Inc now owns 5,987,679 shares of the company’s stock worth $18,562,000 after buying an additional 27,904 shares during the last quarter. 82.09% of the stock is owned by institutional investors.
BioScrip Company Profile
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
Read More: What Factors Can Affect Return on Equity?
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.